PURPOSE Drug-induced uveitis is a rare but sight-threatening condition. We seek to determine the spectrum of drug-induced uveitis at the era of immune checkpoint inhibitors (ICI). METHODS Retrospective pharmacovigilance study based on adverse drug reactions reported within VigiBase, the WHO international pharmacovigilance database. We included deduplicated individual case safety reports (ICSRs) reported as 'uveitis' at Preferred Term level according to the Medical Dictionary for Drug Regulatory Activities between 1967 and 04/28/2019. We performed a case/non-case analysis to study if suspected drug-induced uveitis were differentially reported for each suspected treatment compared to the full database. We excluded drugs with potential indication bias. RESULTS 1404 ICSRs corresponding to 37 drugs had a significant over-reporting signal with a median age of 57 [42-68] years and 45.7% of males. We identified five major groups of treatments: bisphosphonates (26.9%), non-antiviral anti-infectious drugs (25.4%), protein kinase inhibitors (15.5%), ICI (15.0%), and antiviral drugs (11.1%). Severe visual loss was reported in 12.1% of cases. ICI and protein kinase inhibitors were the most recently emerging signals. The time to onset between first infusion and uveitis was significantly different between groups ranging from 5 days [2-19] in the bisphosphonate group to 138.5 [47.25-263.75] in protein kinase inhibitors group (p < 0.0001). Anti-Programmed Cell death 1 represented more than 70% of ICI-induced uveitis. We identified Vogt-Koyanagi-Harada (VKH)-like syndrome as being associated with ICI use. CONCLUSIONS The spectrum of drug-induced uveitis has changed with the evolution of pharmacopeia and the recent emergence of ICIs. VKH-like syndrome has been reported with ICI and protein kinase inhibitors therapy.

中文翻译：

---

在免疫检查点抑制剂时代，药物引起的葡萄膜炎的演变谱来自 WHO 的药物警戒数据库。

目的药物性葡萄膜炎是一种罕见但威胁视力的疾病。我们试图确定免疫检查点抑制剂 (ICI) 时代药物诱发的葡萄膜炎的范围。方法 基于 WHO 国际药物警戒数据库 VigiBase 报告的药物不良反应的回顾性药物警戒研究。根据 1967 年至 2019 年 4 月 28 日期间的药物监管活动医学词典，我们纳入了在首选术语级别报告为“葡萄膜炎”的去重个体病例安全报告 (ICSR)。我们进行了病例/非病例分析，以研究与完整数据库相比，每种疑似治疗的疑似药物性葡萄膜炎的报告是否有差异。我们排除了具有潜在适应证偏倚的药物。结果 37 种药物对应的 1404 个 ICSR 存在显着的高报信号，中位年龄为 57 [42-68] 岁，男性占 45.7%。我们确定了五个主要治疗组：双膦酸盐（26.9%）、非抗病毒抗感染药物（25.4%）、蛋白激酶抑制剂（15.5%）、ICI（15.0%）和抗病毒药物（11.1%）。12.1% 的病例报告了严重的视力丧失。ICI 和蛋白激酶抑制剂是最近出现的信号。从双膦酸盐组的 5 天 [2-19] 到蛋白激酶抑制剂组的 138.5 [47.25-263.75]，各组之间从第一次输注到葡萄膜炎的时间有显着差异（p < 0.0001）。抗程序性细胞死亡 1 占 ICI 诱导的葡萄膜炎的 70% 以上。我们发现 Vogt-Koyanagi-Harada (VKH) 样综合征与 ICI 的使用有关。结论 随着药典的发展和最近 ICI 的出现，药物引起的葡萄膜炎的范围发生了变化。已经报道了 ICI 和蛋白激酶抑制剂治疗的 VKH 样综合征。